Dextrin 2-sulfate(Dextrin 2-sulfate)

概要

基本信息

药物类型

小分子化药

别名

D2S、Dextrin sulphate、Emmelle

+ [1]

靶点-

作用机制

HIV融合抑制剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

衣原体感染HIV感染

原研机构

Vectura Group Ltd.

在研机构-

非在研机构

Vectura Group Ltd.創新股份有限公司

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

20

项与 Dextrin 2-sulfate 相关的临床试验

JPRN-UMIN000053367 / SuspendedN/AIIT

Effects of simultaneous intake of water-soluble liquid konjac and indigestible dextrin on gut microbiota composition in young women: an open-label, cross-over, before-after comparison, dose-dependent study - Effects of simultaneous intake of water-soluble liquid konjac and indigestible dextrin on gut microbiota composition in young women: an open-label, cross-over, before-after comparison, dose-dependent study

开始日期2024-01-16

申办/合作机构

Jumonji University

ChiCTR2200062444 / Suspended早期临床1期IIT

Study on the early intervention effect of dextrin resistance on sugar

开始日期2022-09-01

申办/合作机构

山东大学齐鲁医院

IRCT20150205020965N4 / Completed临床3期IIT

The effect of Camelina oil with and without Resistant dextrin supplementation on metabolic, inflammatory and anti-inflammatory markers in patients with Non-alcoholic fatty liver

开始日期2019-11-15

申办/合作机构

Tabriz University of Medical Sciences

100 项与 Dextrin 2-sulfate 相关的临床结果

登录后查看更多信息

100 项与 Dextrin 2-sulfate 相关的转化医学

登录后查看更多信息

100 项与 Dextrin 2-sulfate 相关的专利（医药）

登录后查看更多信息

861

项与 Dextrin 2-sulfate 相关的文献（医药）

2024-10-01·International Journal of Biological Macromolecules

Facile preparation and characterization of biodegradable and biocompatible UV shielding transdermal patches based on natural rubber latex- dextrin blends

Article

作者: M, Gopika ; Unnikrishnan, G ; Mathew, Mekha Mariam

The physico-chemical and biological properties of natural rubber latex (NRL), entailing its biodegradability and biocompatibility, render it a promising material for various biomedical applications. This research explores the facile blending of NRL with dextrin in different compositions to investigate its potential as a prospective UV shielding transdermal patch for biomedical applications. The superior compatibility between the polymers after blending and the improved thermal stability have been established through FTIR, DSC, and TGA examinations, respectively. Optimization of blended polymers for compatibility, wettability, crystallinity, and static mechanical properties has been performed. Morphology characterization conducted via SEM and AFM techniques suggests a uniform morphology for the optimized blend system. The UV shielding ability of the blend has been confirmed by the evaluation of in-vitro UV shielding performance, UV protection factor (UPF), and the superior protection of the optimized system on living cells upon UV irradiation. The observed cell viability, swelling, erosion, porosity, hemocompatibility, and soil degradation properties suggest the NRL-DXT combination for the possible development of high-quality transdermal patches.

2024-08-01·EFSA Journal

Safety of glucosyl hesperidin as a Novel food pursuant to Regulation (EU) 2015/2283

Article

作者: Vinceti, Marco ; Schlatter, Josef Rudolf ; Matijević, Leonard ; Frenzel, Thomas ; Aguilera-Gómez, Margarita ; Naska, Androniki ; Neuhäuser‐Berthold, Monika ; Siani, Alfonso ; Castenmiller, Jacqueline ; McArdle, Harry J ; Mangelsdorf, Inge ; Hirsch-Ernst, Karen Ildico ; Cubadda, Francesco ; De Henauw, Stefaan ; Kouloura, Eirini ; Turck, Dominique ; Bohn, Torsten ; Knutsen, Helle Katrine ; McArdle, Harry J. ; Maciuk, Alexandre ; Hirsch‐Ernst, Karen Ildico ; Poulsen, Morten ; Heinonen, Marina ; Neuhäuser-Berthold, Monika ; Maradona, Miguel Prieto ; van Loveren, Henk ; Siskos, Alexandros ; Thies, Frank ; Pentieva, Kristina ; De Henauw, Stefaan ; Aguilera‐Gómez, Margarita ; Tsabouri, Sophia

Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on glucosyl hesperidin (GH) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF, which is produced from hesperidin and dextrin by enzymatic reactions, is a powder consisting mainly of monoglucosyl hesperidin (MGH) and unreacted hesperidin (flavonoid), which account in total for up to 92.8% (on dry basis) of the product. The applicant proposed to use the NF in specific drinks and food supplements leading to a maximum intake of up to 364 mg per day for adults. The target population is the general population, except for food supplements for which the proposed target population is children from 1 year onwards and adults. Taking into consideration the composition of the NF and the proposed uses, the consumption of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90‐day oral toxicity study conducted with the NF, the Panel considers the NOAEL at the mid‐dose group, i.e. ~ 1000 mg/kg body weight (bw) per day. By applying an uncertainty factor of 200, the resulting intake providing sufficient margin of exposure for humans would be 5 mg/kg bw per day. The available human intervention studies did not report clinically relevant changes in haematological or clinical chemistry parameters following the administration of GH/MGH at supplemental doses of up to 3 g/day for 12 weeks. Overall, the Panel considers that the margin of exposure (~ 200) between the intake of the NF at the proposed uses and use levels and the NOAEL from the 90‐day study is sufficient. The Panel concludes that the NF, glucosyl hesperidin, is safe for the target population at the proposed uses and use levels.

2024-07-01·Talanta

Dextrin-assisted gel electromembrane extraction of chiral drugs: Improving the extraction efficiency and investigation of enantioselectivity of extraction

Article

作者: Nojavan, Saeed ; Alawadi, Mustafa ; Maghsoudi, Majid ; Fakhari, Ali Reza

The present study investigates the use of dextrins (maltodextrin, β-cyclodextrin, and hydroxypropyl-β-cyclodextrin) to improve the efficiency of the agarose-based gel electromembrane extraction technique for extracting chiral basic drugs (citalopram, hydroxyzine, and cetirizine). Additionally, it examines the enantioselectivity of the extraction process for these drugs. To achieve these, dextrins were incorporated into either the sample solution, the membrane, or the acceptor solution, and then the extraction procedure was performed. Enantiomers were separated and analyzed using a capillary electrophoresis device equipped with a UV detector. The results obtained under the optimal extraction conditions (sample solution pH: 4.0, acceptor solution pH: 2.0, gel membrane pH: 3.0, agarose concentration: 3 % w/v, stirring rate: 1000 rpm, gel thickness: 4.4 mm, extraction voltage: 62.3 V, and extraction time: 32.1 min) indicated that incorporating dextrins into either the sample solution, membrane or the acceptor solution enhances extraction efficiency by 17.3-23.1 %. The most significant increase was observed when hydroxypropyl-β-cyclodextrin was added to the acceptor solution. The findings indicated that the inclusion of hydroxypropyl-β-cyclodextrin in the sample solution resulted in an enantioselective extraction, yielding an enantiomeric excess of 6.42-7.14 %. The proposed method showed a linear range of 5.0-2000 ng/mL for enantiomers of model drugs. The limit of detection and limit of quantification for all enantiomers were found to be < 4.5 ng/mL and <15.0 ng/mL, respectively. Intra- and inter-day RSDs (n = 4) were less than 10.8 %, and the relative errors were less than 3.2 % for all the enantiomers. Finally, the developed method was successfully applied to determine concentrations of enantiomers in a urine sample with relative recoveries of 96.8-99.2 %, indicating good reliability of the developed method.

100 项与 Dextrin 2-sulfate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06496

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
衣原体感染	临床3期	英国	-	-
HIV感染	临床3期	英国	創新股份有限公司	-
HIV感染	临床3期	欧洲	-	-
HIV感染	临床3期	-	Vectura Group Ltd.	-
HIV感染	临床3期	非洲	-	-